127 related articles for article (PubMed ID: 10473985)
1. Detection of prostate-specific antigen- or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: clinical implications.
Millon R; Jacqmin D; Muller D; Guillot J; Eber M; Abecassis J
Eur Urol; 1999 Oct; 36(4):278-85. PubMed ID: 10473985
[TBL] [Abstract][Full Text] [Related]
2. Stage shift in PSA-detected prostate cancers - effect modification by Gleason score.
Pashayan N; Pharoah P; Neal DE; Hamdy F; Donovan J; Martin RM; Greenberg D; Duffy SW
J Med Screen; 2009; 16(2):98-101. PubMed ID: 19564523
[TBL] [Abstract][Full Text] [Related]
3. Promoter methylation of MCAM, ERα and ERβ in serum of early stage prostate cancer patients.
Brait M; Banerjee M; Maldonado L; Ooki A; Loyo M; Guida E; Izumchenko E; Mangold L; Humphreys E; Rosenbaum E; Partin A; Sidransky D; Hoque MO
Oncotarget; 2017 Feb; 8(9):15431-15440. PubMed ID: 28147335
[TBL] [Abstract][Full Text] [Related]
4. Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer.
Cheng HH; Plets M; Li H; Higano CS; Tangen CM; Agarwal N; Vogelzang NJ; Hussain M; Thompson IM; Tewari M; Yu EY
Prostate; 2018 Feb; 78(2):121-127. PubMed ID: 29105802
[TBL] [Abstract][Full Text] [Related]
5. Clinical application of serum tumor abnormal protein in prostate cancer patients.
Fu L; Zhang C; Wang Z; Tao W; Zhu J; Zhou Y; Sun C; Xue B; Yu M; Xu L; Zang Y
BMC Cancer; 2024 May; 24(1):665. PubMed ID: 38822321
[TBL] [Abstract][Full Text] [Related]
6. Accurate prostate cancer detection based on enrichment and characterization of prostate cancer specific circulating tumor cells.
Limaye S; Chowdhury S; Rohatgi N; Ranade A; Syed N; Riedemann J; Patil D; Akolkar D; Datta V; Patel S; Chougule R; Shejwalkar P; Bendale K; Apurwa S; Schuster S; John J; Srinivasan A; Datar R
Cancer Med; 2023 Apr; 12(8):9116-9127. PubMed ID: 36718027
[TBL] [Abstract][Full Text] [Related]
7. Measurement of serum prostate cancer markers using a nanopore thin film based optofluidic chip.
Alzghoul S; Hailat M; Zivanovic S; Que L; Shah GV
Biosens Bioelectron; 2016 Mar; 77():491-8. PubMed ID: 26457734
[TBL] [Abstract][Full Text] [Related]
8. Precise prostate cancer diagnosis using fluorescent nanoprobes for detecting PSA and PSMA in serum.
Ouyang M; Jia M; Chang Z; Wang Y; Wang K; Gao X; Tang B
Chem Commun (Camb); 2024 May; 60(39):5181-5184. PubMed ID: 38647078
[TBL] [Abstract][Full Text] [Related]
9. Galectin-3: a possible complementary marker to the PSA blood test.
Balan V; Wang Y; Nangia-Makker P; Kho D; Bajaj M; Smith D; Heilbrun L; Raz A; Heath E
Oncotarget; 2013 Apr; 4(4):542-9. PubMed ID: 23625538
[TBL] [Abstract][Full Text] [Related]
10. Prostate specific antigen detection in patient sera by fluorescence-free BioCD protein array.
Wang X; Zhao M; Nolte DD; Ratliff TL
Biosens Bioelectron; 2011 Jan; 26(5):1871-5. PubMed ID: 20236816
[TBL] [Abstract][Full Text] [Related]
11. Atopy and prostate cancer: Is there a link between circulating levels of IgE and PSA in humans?
Van Hemelrijck M; Karagiannis SN; Rohrmann S
Cancer Immunol Immunother; 2017 Dec; 66(12):1557-1562. PubMed ID: 28795218
[TBL] [Abstract][Full Text] [Related]
12. New Screening Test Improves Detection of Prostate Cancer Using Circulating Tumor Cells and Prostate-Specific Markers.
Ried K; Tamanna T; Matthews S; Eng P; Sali A
Front Oncol; 2020; 10():582. PubMed ID: 32391268
[TBL] [Abstract][Full Text] [Related]
13. A signal-on built in-marker electrochemical aptasensor for human prostate-specific antigen based on a hairbrush-like gold nanostructure.
Sattarahmady N; Rahi A; Heli H
Sci Rep; 2017 Sep; 7(1):11238. PubMed ID: 28894225
[TBL] [Abstract][Full Text] [Related]
14. Self-sampling of blood using a topper and pediatric tubes; a prospective feasibility study for PSA analysis using 120 prostate cancer patients.
van den Brink N; Even R; Delic E; van Hellenberg Hubar-Fisher S; van Rossum HH
Clin Chem Lab Med; 2023 Nov; 61(12):2159-2166. PubMed ID: 37314986
[TBL] [Abstract][Full Text] [Related]
15. Transformation of proteins into reproductive DNA templates for sensitive quantification of PSA.
Li Z; Fu J; Wang L; Zhou Y; Li J; He S
Talanta; 2024 Jan; 267():125206. PubMed ID: 37716239
[TBL] [Abstract][Full Text] [Related]
16. Prostate Cancer: Genetics, Epigenetics and the Need for Immunological Biomarkers.
Rafikova G; Gilyazova I; Enikeeva K; Pavlov V; Kzhyshkowska J
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628978
[TBL] [Abstract][Full Text] [Related]
17. Spurious results for total and free prostate-specific antigen (PSA); sometimes really "a riddle wrapped in a mystery inside an enigma".
Dorizzi RM; Maltoni P; Sgarzani C; Torello M; Montanari F
Clin Chem Lab Med; 2022 Apr; 60(5):e91-e94. PubMed ID: 35246972
[No Abstract] [Full Text] [Related]
18. Plasma DNA Analysis in Prostate Cancer: Opportunities for Improving Clinical Management.
Wu A; Attard G
Clin Chem; 2019 Jan; 65(1):100-107. PubMed ID: 30538124
[TBL] [Abstract][Full Text] [Related]
19. Identifying biomarkers and surrogates of tumors (cancer biometrics): correlation with immunotherapies and immune cells.
Lotze MT; Rees RC
Cancer Immunol Immunother; 2004 Mar; 53(3):256-61. PubMed ID: 14735318
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer markers: An update.
Pentyala S; Whyard T; Pentyala S; Muller J; Pfail J; Parmar S; Helguero CG; Khan S
Biomed Rep; 2016 Mar; 4(3):263-268. PubMed ID: 26998261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
